Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TFX06 tablets in ER-positive, HER2-negative locally advanced or metastatic breast cancer
CTR20230789Phase 2Active
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TFX06 in breast cancer, sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Started May 2023; status: active.
02
Drugs
TFX06
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230789.